Skip to main
MIST
MIST logo

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals Inc. has demonstrated robust patient outcomes with its lead product, etripamil, which has shown significant improvements in symptom relief and treatment satisfaction, highlighted by a p-value of less than 0.0001 in effectiveness measures. The product’s favorable clinical trial results, including statistically significant improvements in global satisfaction (p=0.0069) and effectiveness (p=0.0015), underscore its potential value in managing atrial fibrillation. Despite existing challenges, the company’s prospects remain optimistic, with analysts suggesting that the current issues raised in the Complete Response Letter (CRL) are manageable, indicating a positive trajectory toward eventual regulatory approval.

Bears say

Milestone Pharmaceuticals Inc has faced significant regulatory and clinical setbacks in recent years, which have negatively impacted investor confidence and contributed to a diminished stock performance. The competitive landscape presents further challenges, as emerging market products may disrupt demand for etripamil, potentially leading to reduced future revenue projections. Additionally, the current high standards for funding diligence in the biopharmaceutical sector have made it difficult for the company to attract investment, exacerbating its financial difficulties.

MIST has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 2 analysts, MIST has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.